MW-301
Parkinson's Disease Psychosis
Phase 1Completed
Key Facts
About MindWalk Holdings
MindWalk Holdings is a clinical-stage biopharmaceutical company dedicated to addressing unmet needs in central nervous system (CNS) disorders. The company's strategy is built on a unique technology platform designed to modulate specific neural pathways with improved safety and efficacy profiles. Its lead programs are advancing in clinical trials for major depressive disorder and Alzheimer's disease. As a public entity, MindWalk aims to translate its scientific insights into transformative treatments for patients with debilitating neurological conditions.
View full company profile